Hyperopic LASEK Treatments with Mitomycin C Using the SCHWIND AMARIS

Purpose: To investigate the outcomes of hyperopic laser epithelial keratomileusis (LASEK) with mitomycin C (MMC) using the SCHWIND AMARIS platform.

Methods: Prospective study of 28 eyes of 14 patients. Mean preoperative manifest spherical equivalent refraction was +2.71±0.72 diopters (D) (range: +1.50 to +4.50 D). All eyes underwent LASEK with an Aberration-Free™ algorithm with the SCHWIND AMARIS followed by a 35-second application of MMC with a 6.7-mm optical zone size.

Results: At 1 year, mean manifest spherical equivalent refraction was 0.03±0.30 D (range: -0.53 to +0.50 D), with 13 eyes within -0.13 to +0.13 D and all 28 eyes within ±0.50 D. Mean uncorrected distance visual acuity was -0.03±0.09 logMAR, and the efficacy and safety indices were 1, respectively, at 1 year. The postoperative manifest spherical equivalent refraction was stable between 1 and 3 months and 1 year.

Conclusions: Hyperopic LASEK with MMC using the SCHWIND AMARIS provided good outcomes in terms of accuracy, efficacy, safety, and stability.